Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Mol Ther ; 32(5): 1561-1577, 2024 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-38454607

RESUMEN

Inflammation resolution is an essential process for preventing the development of chronic inflammatory diseases. However, the mechanisms that regulate inflammation resolution in psoriasis are not well understood. Here, we report that ANKRD22 is an endogenous negative orchestrator of psoriasiform inflammation because ANKRD22-deficient mice are more susceptible to IMQ-induced psoriasiform inflammation. Mechanistically, ANKRD22 deficiency leads to excessive activation of the TNFRII-NIK-mediated noncanonical NF-κB signaling pathway, resulting in the hyperproduction of IL-23 in DCs. This is due to ANKRD22 being a negative feedback regulator for NIK because it physically binds to and assists in the degradation of accumulated NIK. Clinically, ANKRD22 is negatively associated with IL-23A expression and psoriasis severity. Of greater significance, subcutaneous administration of an AAV carrying ANKRD22-overexpression vector effectively hastens the resolution of psoriasiform skin inflammation. Our findings suggest ANKRD22, an endogenous supervisor of NIK, is responsible for inflammation resolution in psoriasis, and may be explored in the context of psoriasis therapy.


Asunto(s)
Modelos Animales de Enfermedad , Interleucina-23 , Psoriasis , Transducción de Señal , Psoriasis/metabolismo , Psoriasis/patología , Psoriasis/terapia , Psoriasis/etiología , Psoriasis/inmunología , Psoriasis/genética , Psoriasis/inducido químicamente , Animales , Ratones , Interleucina-23/metabolismo , Interleucina-23/genética , Humanos , Inflamación/metabolismo , Inflamación/patología , Ratones Noqueados , Piel/patología , Piel/metabolismo , Quinasa de Factor Nuclear kappa B , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Serina-Treonina Quinasas/genética , FN-kappa B/metabolismo
2.
BMC Geriatr ; 24(1): 670, 2024 Aug 09.
Artículo en Inglés | MEDLINE | ID: mdl-39123101

RESUMEN

OBJECTIVE: Previous research has primarily focused on the incidence and mortality rates of Merkel cell carcinoma (MCC), neglecting the examination of cardiovascular mortality (CVM) risk among survivors, particularly older patients. This study aims to assess the risk of CVM in older individuals diagnosed with MCC. METHODS: Data pertaining to older MCC patients were obtained from the Surveillance, Epidemiology, and End Results database (SEER). CVM risk was measured using standardized mortality ratio (SMR) and cumulative mortality. Multivariate Fine-Gray's competing risk model was utilized to evaluate the risk factors contributing to CVM. RESULTS: Among the study population of 2,899 MCC patients, 465 (16.0%) experienced CVM during the follow-up period. With the prolongation of the follow-up duration, the cumulative mortality rate for CVM reached 27.36%, indicating that cardiovascular disease (CVD) became the second most common cause of death. MCC patients exhibited a higher CVM risk compared to the general population (SMR: 1.69; 95% CI: 1.54-1.86, p < 0.05). Notably, the SMR for other diseases of arteries, arterioles, and capillaries displayed the most significant elevation (SMR: 2.69; 95% CI: 1.16-5.29, p < 0.05). Furthermore, age at diagnosis and disease stage were identified as primary risk factors for CVM, whereas undergoing chemotherapy or radiation demonstrated a protective effect. CONCLUSION: This study emphasizes the significance of CVM as a competing cause of death in older individuals with MCC. MCC patients face a heightened risk of CVM compared to the general population. It is crucial to prioritize cardiovascular health starting from the time of diagnosis and implement personalized CVD monitoring and supportive interventions for MCC patients at high risk. These measures are essential for enhancing survival outcomes.


Asunto(s)
Carcinoma de Células de Merkel , Enfermedades Cardiovasculares , Neoplasias Cutáneas , Humanos , Carcinoma de Células de Merkel/mortalidad , Carcinoma de Células de Merkel/epidemiología , Masculino , Anciano , Femenino , Enfermedades Cardiovasculares/mortalidad , Enfermedades Cardiovasculares/epidemiología , Neoplasias Cutáneas/mortalidad , Neoplasias Cutáneas/epidemiología , Anciano de 80 o más Años , Factores de Riesgo , Programa de VERF/tendencias , Estados Unidos/epidemiología , Medición de Riesgo/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA